CHRS Coherus Oncology Inc Forecast, Technical & Fundamental Analysis
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers... Show more
CHRS is expected to report earnings to rise 5.32% to -26 cents per share on July 30
Q2'26
Est.
$-0.26
Q1'26
Est.
$-0.25
Q4'25
Est.
$-0.34
Q3'25
Missed
by $0.01
Q2'25
Missed
by $0.08
The last earnings report on May 11 showed earnings per share of -25 cents, meeting the estimate of -25 cents. With 524.59K shares outstanding, the current market capitalization sits at 241.40M.
A.I. Advisor
published General Information
General Information
a maker of biologic therapeutics for oncology and inflammatory diseases
A.I.dvisor indicates that over the last year, CHRS has been loosely correlated with ARRY. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if CHRS jumps, then ARRY could also see price increases.
The Moving Average Convergence Divergence (MACD) for CHRS turned positive on June 18, 2026. Looking at past instances where CHRS's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CHRS advanced for three days, in of 254 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 46 cases where CHRS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on July 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CHRS as a result. In of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The 50-day moving average for CHRS moved below the 200-day moving average on June 30, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CHRS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for CHRS entered a downward trend on June 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CHRS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.904) is normal, around the industry mean (21.001). P/E Ratio (3.236) is within average values for comparable stocks, (36.006). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). CHRS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (3.860) is also within normal values, averaging (368.009).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CHRS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
